Appendix 1. Current Procedural Terminology (CPT) Codes for Identifying Study Cohorts

Home , Nepafenac

Treatment Category CPT-4 Codes

Uterine Artery Embolization (UAE)# 36247, 37204, 52250, 37210 and require UF dx on claim for each of the codes

Endometrial ablation 56356, 58353, 58563

Hysterectomy

Total abdominal 58150, 58152, 58200,58953, 58954, 58956

Vaginal 58260,58262, 58263, 58267, 58270, 58275, 58280, 58285, 58290-58294

Laparoscopic or robotic 58550, 58552, 58553, 58554, 58541, 58542, 58543, 58544, 58570, 58571, 58572, 58573, 58578#

Subtotal 58180

Radical# 58210, 58548 and require UF diagnosis on claim for each of the codes

Myomectomy

Abdominal 58140, 58146

Vaginal 58145

Laparoscopy 58545,58546, 58551

Borah BJ, Laughlin-Tommaso SK, Myers ER, Yao X, Stewart EA. Association between patient characteristics and treatment procedure among uterine leiomyoma patients. Obstet Gynecol 2015;126. The authors provided this information as a supplement to their article. © Copyright 2015 American College of Obstetricians and Gynecologists. Page 1 of 5

Appendix 2. ICD-9 Codes for Uterine Fibroids and Related Comorbid Conditions

DESCRIPTION ICD-9-CM DIAGNOSIS CODE

Uterine fibroids 218.xx, 219.xx, 654.1x

Menstrual disorders 626.xx

Pelvic pain 625.xx

Anemias 280.xx, 285.xx

Inflammatory diseases 614.xx, 616.xx

Noninflammatory diseases 620.xx, 622.xx

Endometriosis 617.xx

Urinary problems 788.41, 788.20-788.29, 591.xx, 593.5x

Constipation or gas 564.00, 564.09, 787.3 Disorders of the uterus not elsewhere classified 621.xx

Genital prolapse 618.xx

Benign neoplasm of the uterus/ovary 220.xx

Appendix 3. List of NSAIDS and Hormones

Group of Drugs Generic Names

NSAIDS Al Hydroxide/Mg Trisilicate/Phenylbutazone, Antipyrine/Caffeine/Sodium Salicylate, BROMFENAC SODIUM, CELECOXIB, DICLOFENAC POTASSIUM, DICLOFENAC SODIUM, Diclofenac Sodium/Misoprostol, ETODOLAC, FENOPROFEN CALCIUM, FLURBIPROFEN, IBUPROFEN, INDOMETHACIN, KETOPROFEN, Indomethacin Sodium, KETOROLAC TROMETHAMINE, Lansoprazole/Naproxen, MECLOFENAMATE SODIUM, MEFENAMIC ACID, MELOXICAM, NABUMETONE, NAPROXEN, NAPROXEN SODIUM, Nepafenac, OXAPROZIN, Oxyphenbutazone, PHENYLBUTAZONE, PIROXICAM, ROFECOXIB, SULINDAC, TOLMETIN SODIUM, VALDECOXIB Progestins and oral contracetives DESOGESTREL/ETHINYL ESTRADIOL, DROSPIRENONE/ETHINYL ESTRADIOL, ESTONE/PROGESTERONE, Estradiol Cypionate/Medroxyprogesterone Acetate, ESTRONE/TESTOSTERON, Ethinyl Estradiol/Ethynodiol Diacetate, ETHINYL ESTRADIOL/FE FUM/NORETHIN, Ethinyl Estradiol/Ferrous Fum/Norethindrone Ace, Ethinyl Estradiol/Levonorgestrel, ETHINYL ESTRADIOL/NORELGESTROMIN, ETHINYL ESTRADIOL/NORETHIN ACE, Ethinyl Estradiol/Norethindrone, Ethinyl Estradiol/Norethindrone Acetate, ETHINYL ESTRADIOL/NORGESTIMATE, ETHINYL ESTRADIOL/NORGESTREL, HYDROXYPROGESTERONE CAPROATE, LEVONORGESTREL, MEDROXYPROGESTERONE ACETATE, Mestranol/Norethindrone, NORETHINDRONE, NORETHINDRONE ACETATE, NORGESTREL, PROGESTERONE GnRH-a - Gonadotrophin-releasing Abarelix/Sodium Chloride, CETRORELIX ACETATE, FOLLITROPIN BETA/GANIRELIX ACETATE, Ganirelix Acetate, hormone agonist GONADORELIN ACETATE, GONADORELIN HYDROCHLORIDE, GOSERELIN ACETATE, HISTRELIN ACETATE, LEUPROLIDE ACETATE, NAFARELIN ACETATE, TRIPTORELIN PAMOATE Danazol Danazol

Note: NSAIDS: Non-steroidal anti-inflammatory drugs

Appendix 4. Attrition for Women With Surgical Treatments for Uterine Leiomyoma Patients

Female patients age 25-54 in Thomson Reuters Marketscan® Commercial Claims and Encounters Databases between 25,371,009 01/01/2003 and 12/31/2010. Patients with at least one inpatient or two outpatient claims occurring 30 days apart for uterine fibroids (ICD-9-CM 584,425 diagnosis code of 218.xx, 219.xx or 654.1x) occurring on or between 01/01/2003 and 12/31/2010. Patients with any UF procedure occurring on or between 01/01/2004 and 12/31/2009 321,640 Patients continuously enrolled with medical and pharmacy coverage 380 days prior to index date1,2 196,908 Patients continuously enrolled with medical and pharmacy coverage 352 days post index date 2 126,662 Patents with one of the following FOUR study procedures (myomectomy, endometrial ablation, uterine artery 96852 embolization or hysterectomy Myomectomy 7039 Endometrial Ablation 12169 Uterine Artery Embolization 3835 Hysterectomy 73809

1 Index Date is the date of the first surgery 2 Allow for up to a 30 day gap in enrollment

Appendix 5. Marginal Effects of Age and Race Interactions on the Probability of Uterine-Sparing Procedure Compared With

Hysterectomy

Age Group # Marginal Adjusted [95% Race Quintile Effects P-Values† Conf. Interval] 1#1 0.200 0.005 0.037 0.364 1#2 0.217 <0.001 0.149 0.285 1#3 0.354 <0.001 0.304 0.404 1#4 0.426 <0.001 0.390 0.462 1#5 0.500 <0.001 0.474 0.526 2#1 0.167 <0.001 0.114 0.221 2#2 0.199 <0.001 0.177 0.222 2#3 0.224 <0.001 0.210 0.239 2#4 0.243 <0.001 0.232 0.253 2#5 0.304 <0.001 0.294 0.315 3#1 0.138 <0.001 0.094 0.181 3#2 0.169 <0.001 0.151 0.188 3#3 0.177 <0.001 0.166 0.188 3#4 0.189 <0.001 0.180 0.197 3#5 0.218 <0.001 0.208 0.227 Note: Age group 1: 25-34; Age group 2: 35-44; Age group 3: 45-54 †Adjusted p-values are based on Bonferroni correction.